Advertisement


Noelle Cloven, MD, on RAINFOL-03: Actively Recruiting Trial in Pretreated Endometrial Cancer

ASCO 2026

Advertisement

Noelle Cloven, MD, of Texas Oncology, discusses the actively recruiting RAINFOL-03 (ENGOT-EN-31/GOG-3128) study, a global, phase III, open-label, randomized study of rinatabart sesutecan vs investigator’s choice of chemotherapy in patients with endometrial cancer after receipt of platinum-based chemotherapy and PD-L1 inhibition (Abstract TPS5646).



Related Videos

Breast Cancer
Gynecologic Cancers

Siddhartha Yadav, MBBS, MD, on Germline Pathogenic Variants Among Patients With Breast or Ovarian Cancer

Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ovarian cancer (Abstract 10513). 

Hepatobiliary Cancer

Daneng Li, MD, on Tegavivint in Advanced HCC

Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Abstract 4015). 

Bladder Cancer

Shilpa Gupta, MD, on Locally Advanced/Metastatic Urothelial Cancer: Phase III MAIN-CAV Trial

Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-based chemotherapy in patients with locally advanced/metastatic urothelial cancer (Abstract 4514).

Breast Cancer

Yashasvini Sampathkumar, MD, on Job Retention Intervention for Patients Undergoing Breast Cancer Therapy: Digital vs Print Format

Yashasvini Sampathkumar, MD, of Memorial Sloan Kettering Cancer Center, presents data on Talking to Employers and Medical Staff about Work (TEAMWork), an English/Spanish intervention. The English/Spanish intervention, delivered as a booklet or mobile app, was developed to improve work outcomes among women undergoing breast cancer therapy. Dr. Sampathkumar discusses whether the digital vs print format was preferable among this population (Abstract 11060). 

Multiple Myeloma

Dor Abelman, BS, on Multiple Myeloma: cfDNA WGS vs Plasma Proteomics for Minimally Invasive MRD Assessment

Dor Abelman, BS, of the University of Toronto, reviews results of a comparison of two minimally invasive measurable residual disease (MRD) assays—BM-informed cfDNA whole-genome sequencing (cfWGS) and plasma proteomic MRD (EasyM)—in patients with multiple myeloma (Abstract 7546). 

Advertisement

Advertisement




Advertisement